Ahmed Abbas Barh Aljamah (1), Majid Komijani (2)
General Background: Schizophrenia (SCZ) is a chronic and multifactorial neuropsychiatric disorder characterized by disturbances in cognition, emotion, and behavior, affecting approximately one percent of the global population. Specific Background: Recent studies have increasingly implicated neuroinflammation and immune system dysregulation, particularly involving cytokines, in the pathophysiology of SCZ. However, the specific roles and interactions of inflammatory mediators such as interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor-alpha (TNF-α) remain unclear. Knowledge Gap: Limited empirical data exist on how these cytokines correlate with clinical characteristics and demographic factors in SCZ, especially regarding gender differences and their potential as biomarkers. Aims: This study aimed to assess serum levels of IL-8, IL-10, and TNF-α in SCZ patients compared to healthy controls using ELISA and to analyze their interrelationships. Results: Findings revealed significantly higher serum concentrations of IL-8, IL-10, and TNF-α in SCZ patients (p<0.0001), with IL-8 levels notably elevated in female patients. Novelty: This research highlights IL-8 as a gender-sensitive biomarker of neuroinflammation in SCZ, contributing to the understanding of immune involvement in its pathogenesis. Implications: The results suggest that cytokine profiling may aid in identifying inflammatory subtypes of SCZ and support the development of targeted immunomodulatory therapies.Highlight :
The study confirms elevated IL-8, IL-10, and TNF-α levels in SCZ patients compared to controls.
Results suggest that SCZ involves neuro-inflammatory processes linked to immune system activation.
Cytokines may serve as useful biomarkers for developing targeted therapeutic strategies in SCZ.
Keywords : Schizophrenia (SCZ), Neuroinflammation, IL-8, IL-10, Tumor Necrosis Factor-alpha (TNF-α)
Sadock BJ, Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2007.
Rosell DR, Futterman SE, McMaster A, Siever LJ, Schizotypal Personality Disorder: A Current Review, Current Psychiatry Reports, vol. 16, no. 7, pp. 1–12, 2014.
Arinami T, Ohtsuki T, Ishiguro H, Ujike H, Tanaka Y, Morita Y, et al., Genomewide High-Density SNP Linkage Analysis of 236 Japanese Families Supports the Existence of Schizophrenia Susceptibility Loci on Chromosomes 1p, 14q, and 20p, The American Journal of Human Genetics, vol. 77, no. 6, pp. 937–944, 2005.
Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB, Inflammation and Immunity in Schizophrenia: Implications for Pathophysiology and Treatment, The Lancet Psychiatry, vol. 2, no. 3, pp. 258–270, 2015.
DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW, et al., A Genome-Wide Scan for Linkage to Chromosomal Regions in 382 Sibling Pairs with Schizophrenia or Schizoaffective Disorder, American Journal of Psychiatry, vol. 159, no. 5, pp. 803–812, 2002.
Raedler TJ, Knable MB, Weinberger DR, Schizophrenia as a Developmental Disorder of the Cerebral Cortex, Current Opinion in Neurobiology, vol. 8, no. 1, pp. 157–161, 1998.
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B, Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects, Biological Psychiatry, vol. 70, no. 7, pp. 663–671, 2011.
Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E, Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review, Biological Psychiatry, vol. 63, no. 8, pp. 801–808, 2008.
Upthegrove R, Manzanares-Teson N, Barnes NM, Cytokine Function in Medication-Naive First Episode Psychosis: A Systematic Review and Meta-Analysis, Schizophrenia Research, vol. 155, no. 1–3, pp. 101–108, 2014.
Anders S, Kinney DK, Abnormal Immune System Development and Function in Schizophrenia Helps Reconcile Diverse Findings and Suggests New Treatment and Prevention Strategies, Brain Research, vol. 1617, pp. 93–112, 2015.
Chou CY, Ma MC, Yang TT, Determinants of Subjective Health-Related Quality of Life (HRQoL) for Patients with Schizophrenia, Schizophrenia Research, vol. 154, no. 1–3, pp. 83–88, 2014.
Shah K, Maghsoudlou P, Enzyme-Linked Immunosorbent Assay (ELISA): The Basics, British Journal of Hospital Medicine, vol. 77, no. 7, pp. C98–C101, 2016.
Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC, Elevated Interleukin-2, Interleukin-6 and Interleukin-8 Serum Levels in Neuroleptic-Free Schizophrenia: Association with Psychopathology, Schizophrenia Research, vol. 57, no. 2–3, pp. 247–258, 2002.
Ahn S, Corwin EJ, The Association Between Breastfeeding, the Stress Response, Inflammation, and Postpartum Depression During the Postpartum Period: Prospective Cohort Study, International Journal of Nursing Studies, vol. 52, no. 10, pp. 1582–1590, 2015.
Boerrigter D, Weickert TW, Lenroot R, O’Donnell M, Galletly C, Liu D, et al., Using Blood Cytokine Measures to Define High Inflammatory Biotype of Schizophrenia and Schizoaffective Disorder, Journal of Neuroinflammation, vol. 14, no. 1, pp. 1–15, 2017.
Balõtšev R, Koido K, Vasar V, Janno S, Kriisa K, Mahlapuu R, et al., Inflammatory, Cardio-Metabolic and Diabetic Profiling of Chronic Schizophrenia, European Psychiatry, vol. 39, pp. 1–10, 2017.
Dahan S, Bragazzi NL, Yogev A, Bar-Gad M, Barak V, Amital H, et al., The Relationship Between Serum Cytokine Levels and Degree of Psychosis in Patients with Schizophrenia, Psychiatry Research, vol. 268, pp. 467–472, 2018.
Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L, et al., Serum and Gene Expression Profile of Cytokines in First-Episode Psychosis, Brain, Behavior, and Immunity, vol. 31, pp. 90–95, 2013.
Asevedo E, Gadelha A, Noto C, Mansur RB, Zugman A, Belangero SI, et al., Impact of Peripheral Levels of Chemokines, BDNF and Oxidative Markers on Cognition in Individuals with Schizophrenia, Journal of Psychiatric Research, vol. 47, no. 10, pp. 1376–1382, 2013.
Dennison U, McKernan D, Cryan J, Dinan T, Schizophrenia Patients with a History of Childhood Trauma Have a Pro-Inflammatory Phenotype, Psychological Medicine, vol. 42, no. 9, pp. 1865–1871, 2012.
Dimitrov DH, Lee S, Yantis J, Valdez C, Paredes RM, Braida N, et al., Differential Correlations Between Inflammatory Cytokines and Psychopathology in Veterans with Schizophrenia: Potential Role for IL-17 Pathway, Schizophrenia Research, vol. 151, no. 1–3, pp. 29–35, 2013.
Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M, Serum IL-1β, sIL-2R, IL-6, IL-8 and TNF-α in Schizophrenic Patients, Relation with Symptomatology and Responsiveness to Risperidone Treatment, Mediators of Inflammation, vol. 10, no. 3, pp. 109–115, 2001.
Rao JS, Kim HW, Harry GJ, Rapoport SI, Reese EA, Increased Neuroinflammatory and Arachidonic Acid Cascade Markers, and Reduced Synaptic Proteins, in the Postmortem Frontal Cortex from Schizophrenia Patients, Schizophrenia Research, vol. 147, no. 1, pp. 24–31, 2013.
Severance EG, Alaedini A, Yang S, Halling M, Gressitt KL, Stallings CR, et al., Gastrointestinal Inflammation and Associated Immune Activation in Schizophrenia, Schizophrenia Research, vol. 138, no. 1, pp. 48–53, 2012.
Battaglia M, Fossati A, Torgersen S, Bertella S, Bajo S, Maffei C, et al., A Psychometric–Genetic Study of Schizotypal Disorder, Schizophrenia Research, vol. 37, no. 1, pp. 53–64, 1999.
Larsson MK, Schwieler L, Goiny M, Erhardt S, Engberg G, Chronic Antipsychotic Treatment in the Rat–Effects on Brain Interleukin-8 and Kynurenic Acid, International Journal of Tryptophan Research, vol. 8, pp. 45–52, 2015.
Mednova IA, Boiko AS, Kornetova EG, Semke AV, Bokhan NA, Ivanova SA, Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia, Life, vol. 12, no. 12, p. 1972, 2022.
Babulas V, Factor-Litvak P, Goetz R, Schaefer CA, Brown AS, Prenatal Exposure to Maternal Genital and Reproductive Infections and Adult Schizophrenia, American Journal of Psychiatry, vol. 163, no. 5, pp. 927–929, 2006.
Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, et al., Elevated Maternal Interleukin-8 Levels and Risk of Schizophrenia in Adult Offspring, American Journal of Psychiatry, vol. 161, no. 5, pp. 889–895, 2004.
Picker J, The Role of Genetic and Environmental Factors in the Development of Schizophrenia, Psychiatric Times, vol. 22, no. 9, pp. 29–32, 2005.
Dazzan P, Schizophrenia During Pregnancy, Current Opinion in Psychiatry, vol. 34, no. 3, pp. 238–244, 2021.
Ormel PR, Bottcher C, Gigase FA, Missall RD, van Zuiden W, Zapata MCF, et al., A Characterization of the Molecular Phenotype and Inflammatory Response of Schizophrenia Patient-Derived Microglia-Like Cells, Brain, Behavior, and Immunity, vol. 90, pp. 196–207, 2020.
Shelton HW, Gabbita SP, Gill WD, Burgess KC, Whicker WS, Brown RW, The Effects of a Novel Inhibitor of Tumor Necrosis Factor Alpha on Prepulse Inhibition and Microglial Activation in Two Distinct Rodent Models of Schizophrenia, Behavioural Brain Research, vol. 406, p. 113229, 2021.
Comer AL, Carrier M, Tremblay ME, Cruz-Martin A, The Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation, Frontiers in Cellular Neuroscience, vol. 14, p. 274, 2020.
Pandurangi AK, Buckley PF, Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-Inflammatory Agents in Schizophrenia, Neuroinflammation and Schizophrenia, pp. 227–244, 2020.
Shnayder NA, Khasanova AK, Strelnik AI, Al-Zamil M, Otmakhov AP, Neznanov NG, et al., Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia, International Journal of Molecular Sciences, vol. 23, no. 19, p. 11324, 2022.
Maes M, Chiavetto LB, Bignotti S, Tura GJB, Pioli R, Boin F, et al., Increased Serum Interleukin-8 and Interleukin-10 in Schizophrenic Patients Resistant to Treatment with Neuroleptics and the Stimulatory Effects of Clozapine on Serum Leukemia Inhibitory Factor Receptor, Schizophrenia Research, vol. 54, no. 3, pp. 281–291, 2002.
Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M, et al., Cytokines Production in Chronic Schizophrenia Patients with or Without Paranoid Behaviour, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 22, no. 6, pp. 947–957, 1998.
O’Brien SM, Scully P, Dinan TG, Increased Tumor Necrosis Factor-Alpha Concentrations with Interleukin-4 Concentrations in Exacerbations of Schizophrenia, Psychiatry Research, vol. 160, no. 3, pp. 256–262, 2008.
Kubistova A, Horacek J, Novak T, Increased Interleukin-6 and Tumor Necrosis Factor Alpha in First Episode Schizophrenia Patients Versus Healthy Controls, Psychiatria Danubina, vol. 24, suppl. 1, pp. 153–156, 2012.
Lammers KM, Brigidi P, Vitali B, Gionchetti P, Rizzello F, Caramelli E, et al., Immunomodulatory Effects of Probiotic Bacteria DNA: IL-1 and IL-10 Response in Human Peripheral Blood Mononuclear Cells, FEMS Immunology & Medical Microbiology, vol. 38, no. 2, pp. 165–172, 2003.
Rodrigues-Amorim D, Rivera-Baltanas T, Spuch C, Caruncho HJ, Gonzalez-Fernandez A, Olivares JM, et al., Cytokines Dysregulation in Schizophrenia: A Systematic Review of Psychoneuroimmune Relationship, Schizophrenia Research, vol. 197, pp. 19–33, 2018.
Al-Asmary SM, Kadasah S, Arfin M, Tariq M, Al-Asmari A, Genetic Variants of Interleukin-10 Gene Promoter Are Associated with Schizophrenia in Saudi Patients: A Case-Control Study, North American Journal of Medical Sciences, vol. 6, no. 11, pp. 558–562, 2014.
Breit S, Kupferberg A, Rogler G, Hasler G, Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders, Frontiers in Psychiatry, vol. 9, p. 44, 2018.
Müller N, Myint AM, Schwarz MJ, The Impact of Neuroimmune Dysregulation on Neuroprotection and Neurotoxicity in Psychiatric Disorders: Relation to Drug Treatment, Dialogues in Clinical Neuroscience, vol. 24, pp. 315–329, 2022.